Solid Biosciences Inc. Common Stock (SLDB) is a publicly traded Healthcare sector company. As of July 28, 2026, SLDB trades at $7.87 with a market cap of $770.86M and a P/E ratio of -4.03. SLDB moved -0.20% today. Year to date, SLDB is +39.89%; over the trailing twelve months it is +12.71%. Its 52-week range spans $2.41 to $11.45. Analyst consensus is strong buy with an average price target of $16.75. Rallies surfaces SLDB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BioGene Therapeutics Adds Veteran Biopharma Executive Ty Howton to Board: BioGene Therapeutics has added Ty Howton, ex-COO of Solid Biosciences and former General Counsel at Vertex and Sarepta, to its Board. Howton’s 30-year biopharma tenure includes overseeing multiple equity financings, debt facilities and advancing gene therapy candidates into active clinical trials.
| Metric | Value |
|---|---|
| Price | $7.87 |
| Market Cap | $770.86M |
| P/E Ratio | -4.03 |
| EPS | $-1.99 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.45 |
| 52-Week Low | $2.41 |
| Volume | 449 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-174.32M |
| Gross Margin | 0.00% |
9 analysts cover SLDB: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $16.75.